Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Buscopan Plus

Approved

STANDARD

Buscopan Plus

Sanofi Vietnam Shareholding Company🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: ca4207e09905c2e5
Company: Sanofi Vietnam Shareholding Company
Type: Standard

Approval Details

Approval Id: ca4207e09905c2e5
Drug Approval Philippines Name: Buscopan Plus
Product Name: Buscopan Plus
Registration Number: DRP-3039
Brand Name: Buscopan Plus
Generic Name: Hyoscine-N-Butylbromide + Paracetamol
Dosage Form: Film Coated Tablet
Dosage Strength: 10 mg /500 mg
Manufacturer: Sanofi Vietnam Shareholding Company
Importer: Opella Healthcare Philippines, Inc.
Issuance Date: 24 November 2022
Expiry Date: 31 May 2027
Classification: Over-the-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

ca4207e09905c2e5

Type

Standard

Back to Philippines FDA Approvals

Buscopan Plus - Philippines FDA Drug Approval Details